Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.074
Buy
RSI(14)
57.250
Neutral
STOCH(KDJ)(9,3,3)
67.879
Neutral
ATR(14)
0.170
High Vlolatility
CCI(14)
50.995
Neutral
Williams %R
24.409
Buy
TRIX(12,20)
0.518
Sell
StochRSI(14)
0.000
Sell
Search
ALX Oncology Holdings Inc
ALXOAdd to Watchlist
2.030USD
-0.010-0.49%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
273.16MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of ALX Oncology Holdings Inc
Currency: USD Updated: 2026-05-15Key Insights
ALX Oncology Holdings Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 103 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.60.In the medium term, the stock price is expected to trend down.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ALX Oncology Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
ALX Oncology Holdings Inc Highlights
StrengthsRisks
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.
Fairly Valued
The company’s latest PE is -1.36, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 51.67M shares, decreasing 7.07% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 423.10K shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
4.600
Target Price
+125.49%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of ALX Oncology Holdings Inc is 5.40, ranking 360 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
2.04
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.20
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
ALX Oncology Holdings Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of ALX Oncology Holdings Inc is 8.74, ranking 24 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.36, which is -87.84% below the recent high of -0.17 and -247.31% above the recent low of -4.73.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 103/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of ALX Oncology Holdings Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 3.00, with a high of 4.00 and a low of 2.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
4.600
Target Price
+125.49%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
ALX Oncology Holdings Inc
ALXO
7
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of ALX Oncology Holdings Inc is 8.42, ranking 54 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.31 and the support level at 1.63, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.042
Sell
MA10
2.006
Buy
MA20
1.834
Buy
MA50
1.914
Buy
MA100
1.835
Buy
MA200
1.581
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of ALX Oncology Holdings Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 38.46%, representing a quarter-over-quarter decrease of 62.05%. The largest institutional shareholder is James Simons, holding a total of 423.10K shares, representing 0.31% of shares outstanding, with 1073.13% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of ALX Oncology Holdings Inc is 1.89, ranking 261 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.45. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. ALX Oncology Holdings Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.46
VaR
+9.30%
240-Day Maximum Drawdown
+50.46%
240-Day Volatility
+114.79%
Return
Best Daily Return
60 days
+12.07%
120 days
+14.60%
5 years
+56.13%
Worst Daily Return
60 days
-10.53%
120 days
-10.74%
5 years
-41.67%
Sharpe Ratio
60 days
-0.30
120 days
+1.19
5 years
-0.22
Risk Assessment
Maximum Drawdown
240 days
+50.46%
3 years
+97.69%
5 years
+99.50%
Return-to-Drawdown Ratio
240 days
+5.22
3 years
-0.25
5 years
-0.19
Skewness
240 days
+1.58
3 years
+1.39
5 years
+1.12
Volatility
Realised Volatility
240 days
+114.79%
5 years
+104.90%
Standardised True Range
240 days
+7.11%
5 years
+40.77%
Downside Risk-Adjusted Return
120 days
+231.49%
240 days
+231.49%
Maximum Daily Upside Volatility
60 days
+60.61%
Maximum Daily Downside Volatility
60 days
+55.33%
Liquidity
Average Turnover Rate
60 days
+1.73%
120 days
+1.24%
5 years
--
Turnover Deviation
20 days
+16.09%
60 days
+9.25%
120 days
-21.88%
Peer Comparison
Biotechnology & Medical Research
ALX Oncology Holdings Inc
ALXO
6.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
